Breaking barriers in leptomeningeal disease: A Society for Neuro-Oncology and The American Society of Clinical Oncology consensus review on clinical trial design and basic science integration
Neuro-Oncology · 2026-05-27
Molecular therapy of glioblastoma, IDH-wildtype
Elsevier eBooks · 2026-01-01
Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma
Neuro-Oncology · 2025-12-13 · 4 citations
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitors
Neuro-Oncology Advances · 2025-12-08
Supplementary Data 1 from Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients
2025-11-25
IMG-21. Prognostic significance of contrast enhancement in newly diagnosed grade 2 <i>IDH</i> -mutant glioma
Neuro-Oncology · 2025-11-01
IMG-125. Differentiating tumor progression from pseudoprogression in glioma patients using MR elastography
Neuro-Oncology · 2025-11-01
NCOG-43. Clinical outcomes in patients with molecular vs histological glioblastoma
Neuro-Oncology · 2025-11-01
CTIM-12. DUAL IMMUNE CHECKPOINT BLOCKADE FOR SURGICALLY ACCESSIBLE RECURRENT GLIOBLASTOMA: CLINICAL AND MOLECULAR OUTCOMES
Neuro-Oncology · 2025-11-01
DISP-30. Impact of distance traveled for clinical trial participation on clinical outcomes in patients with glioblastoma
Neuro-Oncology · 2025-11-01
CTIM-31. SAFETY AND TOLERABILITY OF OLAPARIB, TEMOZOLOMIDE, AND PEMBROLIZUMAB IN A PHASE 2 TRIAL IN PATIENTS WITH PROGRESSIVE GLIOBLASTOMA
Neuro-Oncology · 2025-11-01
NCOG-14. Deficits in Gait Quantified by Large Language Model-derived NANO Scores Predict Survival in High-grade Glioma
Neuro-Oncology · 2025-11-01
Supplementary Data1 from Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma
2025-09-02
Data from Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type GlioblastomaPreprint
2025-09-02
Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Neuro-Oncology · 2025-07-22 · 39 citations
RANO seizure working group-Tumor-Related Epilepsy Assessment Tool (RANO-TREAT) to assess seizure control for glioma treatment trials and clinical practice
Neuro-Oncology · 2025-07-08 · 4 citations
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma
Clinical Cancer Research · 2025-07-01 · 2 citations
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4
Neuro-Oncology · 2025-05-29 · 6 citations
Safety and tolerability of olaparib, temozolomide, and pembrolizumab in a phase 2 trial in patients with progressive glioblastoma.
Journal of Clinical Oncology · 2025-05-28
Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report
Neuro-Oncology · 2025-05-03 · 8 citations